ACM
VERV

Aquatic Capital Management’s Verve Therapeutics VERV Stock Holding History

Aquatic Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,100
Closed -$45K – 1764
2023
Q1 		$45K Buy
+3,100
New +$60.7K ﹤0.01% 914

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Aquatic Capital Management's VERV Position: Q2 2023 in Review

Aquatic Capital Management sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 3,100 shares — an estimated $45K sold.

Aquatic Capital Management first reported a position in VERV in Q1 2023 and held it in 1 quarter. The position peaked at $45K in Q1 2023. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • Aquatic Capital Management reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 3,100 Verve Therapeutics shares in Q2 2023, an estimated $45K.
  • Aquatic Capital Management first reported a position in Verve Therapeutics in Q1 2023 and held it in 1 quarter.
  • Aquatic Capital Management's Verve Therapeutics position peaked at $45K in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on Aquatic Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.